Monthly research recap
Cannabis research: September 2026
What September 2026's 15 new studies found, synthesized from the papers below. All Cannabis research →
The synthesis
Synthesized from 15 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Cannabis, marijuana, THC, tetrahydrocannabinol, then ranked by relevance.
Research indexed in September 2026 on cannabis was mostly preclinical, observational, and theoretical rather than definitive clinical trials. The most consistent signals were harm-related: cannabis use predicted early psychiatric readmission in young adults with bipolar or psychotic disorders, and cannabis use interacted with psychosis vulnerability to worsen borderline personality symptoms. Cognitive and affective findings were mixed and dose- or chemovar-dependent, and several key results come from animal models or small samples, so durability and generalizability remain uncertain.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Impact of Cannabis Use on Time to Psychiatric Rehospitalization in Young Adults With Bipolar and Psychotic Disorders: A Survival Analysis. 2026 | historical cohort | 200 | Opposes | Cannabis use at admission predicted psychiatric readmission within the first month (HR=2.8) and at 3 months (HR=1.9), with the association becoming nonsignificant by 6 months. |
| The Artifact Hypothesis: Deconstructing Schizophrenia Through the Lens of Prohibition, Adulterated Cannabis, and Neurodevelopmental Psychopathology 2026 | theoretical or philosophical paper | Unclear | Argues that a substantial share of youth schizophrenia diagnoses may be a diagnostic artifact of prohibition-era policy and high-potency adulterated cannabis, and advocates dimensional psychopathology models. | |
| HPLC ‐ UV quantitation of synthetically derived THC , THCP , and HHC isomers in commercial vaping liquids and edibles (2019–2024) 2026 | analytical chemistry study | Opposes | Synthetic THC products contained variable and sometimes very high total THC isomer content (25-96% w/w in vaping liquids and dabs; up to 791 mg per gummy), and the authors validated HPLC-UV methods to quantify these isomers. | |
| Prenatal Δ9-tetrahydrocannabinol exposure rewires glucocorticoid-hippocampal crosstalk and impairs memory under stress in adolescent rat offspring. 2026 | experimental animal study | Opposes | Prenatal THC exposure in rats produced stress-related search strategies, delayed learning, and impaired memory with elevated glucocorticoids and reduced hippocampal receptor balance and BDNF; metyrapone rescued memory and normalized these markers. | |
| Cue-elicited prefrontal gamma-aminobutyric acid (GABA) dynamics in cannabis use disorder. 2026 | case-control study | 41 | Mixed | Overall prefrontal GABA+ levels were similar between groups, but the cannabis use disorder group showed increased GABA+ during cannabis cue reactivity versus neutral cues. |
| Cognitive Outcomes among Cannabis Users with and without a History of Polysubstance Use 2026 | observational study | Mixed | Polysubstance users scored 2.41 points higher on planning than cannabis-only users, while greater daily cannabis quantity was associated with blunted stress cortisol response, lower impulsivity and memory scores, and higher risk aversion; the authors characterized group differences as minimal and quantity findings as unexpected. | |
| Cannabis Use Interacts With Psychosis Vulnerability in Borderline Personality Disorder: La consommation de cannabis interagit avec la vulnérabilité à la psychose dans le trouble de la personnalité limite 2026 | cross-sectional clinical study with moderation analyses | 79 | Mixed | Cannabis use moderated the association between psychotic-like experiences and BPD symptom severity, strengthening it as cannabis use increased, with a crossover such that cannabis use was negatively associated with BPD symptoms among those with low psychotic-like experiences. |
| 769. Can the genetic of liver enzyme involved in THC metabolism tell us who are the cannabis users at greater risk of psychosis? 2026 | genetic association study | Supports | Variation in a genetic risk score for CYP3A4 expression was associated with differences in paranoia scores and likelihood of reporting psychotic-like experiences among cannabis users in two samples, suggesting faster THC metabolism may reduce psychotomimetic effects. | |
| Cannabis Is a Psychedelic, and a Beneficial One at That - The Overlooked Cannabinoid Path Into Altered Consciousness 2026 | theoretical or philosophical paper | Mixed | Argues that cannabis is phenomenologically psychedelic and medically useful in several established contexts while carrying risks including anxiety, cognitive impairment, psychosis vulnerability, and cannabis use disorder, with effects shaped by dose, biology, expectations, and setting. | |
| "Cannabis Green Wave" versus "Nicotine Freeze": the regulatory paradox of cannabis liberalization and nicotine prohibition. 2026 | theoretical or philosophical paper | Unclear | Argues that cannabis liberalization and nicotine restriction reflect a regulatory double standard driven by political ideology rather than toxicological evidence, and proposes a consistent risk-proportionate harm-reduction paradigm. | |
| Tolerance, physical dependence, and Δ9-THC-like interoceptive effects of cannabinol in mice. 2026 | preclinical animal study | Opposes | Repeated cannabinol administration in mice produced tolerance to cannabimimetic effects and physical dependence with rimonabant-precipitated withdrawal; cannabinol fully substituted for THC and attenuated THC's psychoactive effects. | |
| Effects of delta-9 tetrahydrocannabinol and cannabidiol on cognitive outcomes following acute use of cannabis for chronic pain. 2026 | observational study | 183 | Mixed | CBD-dominant users outperformed CBD+THC users in working memory one hour post-use and had more stable verbal learning than THC or CBD+THC users, with no significant effects on executive function, episodic memory, or processing speed. |
| Cannabis and Christianity: Scientific, Social, and Theological Reflections on THC and Christian Faith 2026 | review | Unclear | Argues that a Christian ethical perspective on THC use must integrate neurobiological, clinical, public health, and social evidence with theological frameworks and distinguish medical, recreational, and spiritual contexts. | |
| Adolescent Exposure to a THC-Rich Cannabis Extract Produces Genotype-Dependent Effects on Cognition and Glial Morphology in Serine Racemase Mutant Mice. 2026 | controlled animal experimental study | Mixed | Adolescent THC-rich cannabis extract prevented prepulse inhibition and spatial object recognition deficits and attenuated glial alterations in adult mutant mice, while transiently impairing sensorimotor gating and inducing a distinct astrocytic phenotype in wild-type mice. | |
| Physical Activity Level Moderates Cannabis-Associated Reductions in Negative Affect in Anxious Individuals. 2026 | secondary analysis of a randomized controlled trial | 178 | Mixed | Negative affect decreased over time in all cannabis groups, but in the THC-dominant group higher daily moderate-to-vigorous physical activity was associated with a less steep decrease in negative affect, a moderation not seen in CBD-dominant or THC+CBD groups. |
Points of agreement
- Cannabis use is repeatedly linked to psychosis-related risk: early psychiatric readmission in bipolar/psychotic disorders, stronger psychotic-like experience-BPD symptom association, and theoretical concern about high-potency products.
- Effects of cannabis on cognition and affect are heterogeneous and depend on cannabinoid composition (CBD vs THC), dose, and individual factors such as genetic background and psychosis vulnerability.
- Several studies highlight high-potency or synthetically derived THC products as a distinct concern, with variable and sometimes very high THC isomer content.
Conflicts
- Some findings point to harm (increased readmission, worsened BPD symptoms with high psychotic-like experiences, prenatal THC cognitive deficits), while others show benefit or no effect (CBD-dominant cognitive advantage, THC-rich extract preventing deficits in mutant mice, similar overall GABA+ levels).
- Cannabis is characterized both as a risky substance with psychosis and cognitive harms and as a medically useful, phenomenologically psychedelic agent with therapeutic applications.
- Quantity-related cognitive findings in one observational study were described as unexpected and contrary to typical expectations, conflicting with harm-oriented results elsewhere.
Gaps
- Durability of effects beyond 6 months is largely unexamined; the readmission association became nonsignificant by 6 months.
- Most evidence is preclinical (rodent) or observational; few randomized controlled trials directly test cannabis effects on psychiatric or cognitive outcomes.
- Small samples in several clinical studies limit generalizability and precision.
- Dose, potency, and chemovar are inconsistently characterized, especially for synthetic and high-THC products.
- Populations studied are narrow (young adults with bipolar/psychotic disorders, BPD outpatients, chronic low back pain, anxious individuals), leaving other groups unstudied.
- Blinding and expectancy effects are rarely addressed in self-selected cannabis studies.